Intermountain Healthcare just announced it has chosen Elsevier’s Via Oncology to provide Clinical Pathways Solutions for Intermountain’s Oncology Clinical Program. Via Oncology’s Via Pathways helps cancer centers demonstrate the value of their care to patients, referring physicians and payers, by developing and implementing clinical pathways in collaboration with its network of more than 1,500 US cancer care providers.
Via Oncology’s Via Pathways includes evidence-based proprietary content developed by committees composed of leading oncologists that forms the basis of clinical algorithms covering 95 percent of cancer types treated in the US.
That means Via Oncology’s evidence-based proprietary content is now available to physicians and their staff at the point of care. Intermountain’s Oncology Clinical Program has a system role to ensure optimal cancer care delivery. Intermountain’s cancer disease-specific development teams conduct quality improvement and cancer care delivery research designed to improve treatment options and outcomes for our cancer patients, while reducing system variation and cost.
Intermountain is already a valued Elsevier customer utilizing Elsevier’s ClinicalKey digital medical reference platform and now its clinicians and patients will benefit from the standardized, evidence-based clinical pathways from Via Oncology too.
“Oncology pathways are dynamic – changing as new and improved screening and diagnostic techniques are validated, as investigational therapeutics make their way thru FDA approval, and as other cancer care delivery advancements occur,” said Brad Bott, Operations Director for Intermountain’s Oncology Clinical Program in a statement. “Intermountain Healthcare and the Oncology Clinical Program’s strategic partnership with Via Oncology is a testament to our commitment to ensure all cancer patients in our healthcare system receive access to the highest quality, evidence-based cancer care, at the lowest possible cost.”
